Pioglitazone protects against cisplatin induced nephrotoxicity in rats and potentiates its anticancer activity against human renal adenocarcinoma cell lines

Food and Chemical Toxicology

Volumn 51, Issue 1, 2013, Pages 114-122

  Mahmoud, Mona F ^a   El Shazly, Shimaa M ^a  

^a Zagazig University   (Egypt)

Author keywords

BADGE; Cisplatin; Nephrotoxicity; Pioglitazone; PPAR

Indexed keywords

BISPHENOL A BIS(2 HYDROXYPROPYL) ETHER DIMETHACRYLATE; CISPLATIN; CREATININE; GLUTATHIONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MALONALDEHYDE; NITROGEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CARCINOMA CELL; CELL VIABILITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG POTENTIATION; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MALE; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; RAT; RENAL PROTECTION; UREA BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL;

ANIMALS; BENZHYDRYL COMPOUNDS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CISPLATIN; EPOXY COMPOUNDS; GENE EXPRESSION; HUMANS; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; KIDNEY NEOPLASMS; MALE; NF-KAPPA B; OXIDATIVE STRESS; PPAR GAMMA; PROTECTIVE AGENTS; RATS; RATS, WISTAR; THIAZOLIDINEDIONES; TUMOR NECROSIS FACTOR-ALPHA;

RATTUS;

EID: 84867284226     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2012.09.006     Document Type: Article

References (47)

1. Arany I., Safirstein R.L. Cisplatin nephrotoxicity. Semin. Nephrol 2003, 23:460-464.
2. Arany I., Megyesi J.K., Kaneto H., Price P.M., Safirstein R.L. Cisplatin induced cell death is EGFR/src/ERK signaling dependent in mouse proximal tubule cells. Am. J. Physiol. Renal Physiol. 2004, 287:F543-F549.
3. Beutler E., Durgun O., Kelly B.M. Improved method for the determination of blood glutathione. J. Lab. Clin. Med. 1963, 51:882-888.
4. Bowers L.D., Wong E.T. Kinetic serum creatinine assays. II. A critical evaluation and review. Clin. Chem. 1980, 26(5):555-561.
5. Brown J.D., Plutzky J. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation 2007, 115:518-533.
6. Chaney S.G., Campbell S.L., Temple B., Bassett E., Wu Y., Faldu M. Protein interactions with platinum-DNA adduct, from structure to function. J. Inorg. Biochem. 2004, 98:1551-1559.
7. Curran W.J. New chemotherapeutic agents, update of major chemo radiation trials in solid tumors. Oncology 2002, 63(Suppl 2):29-38.
8. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., Skene A.M., Tan M.H., Lefebvre P.J., Murray G.D., Standl E., Wilcox R.G., Wilhelmsen L., Betteridge J., Birkeland K., Golay A., Heine R.J., Koranyi L., Laakso M., Mokan M., Norkus A., Pirags V., Podar T., Scheen A., Scherbaum W., Schernthaner G., Schmitz O., Skrha J., Smith U., Taton J., Proactive investigators Secondary prevention of macrovascular events in patients with type 2 diabetes in the Proactive Study (prospective pioglitazone clinical trial in macrovascular events), a randomized controlled trial. Lancet 2005, 366:1279-1289.
9. El-Hage, J., 2005. Peroxisome proliferator-activated receptor agonists: carcinogenicity findings and regulatory recommendations. International Atherosclerosis Society Symposium on PPAR, Monte Carlo.
10. Faubel S.L., Jubanovic D., Reznikov L., Somerset H., Dinarello C.A., Edelstein C.L. Caspase-1-deficient mice are protected against cisplatin induced apoptosis and acute tubular necrosis. Kidney Int. 2004, 66:2202-2213.
11. Girnun G.D., Domann F.E., Moore S.A., Robbins M.E. Identification of a functional peroxisome proliferator-activated receptor response element in the rat catalase promoter. Mol. Endocrinol. 2002, 16:2793-2801.
12. Goldberg R.B., Kendall D.M., Deeg M.A., Buse J.B., Zagar A.J., Pinaire J.A., Tan M.H., Khan M.A., Perez A.T., Jacober S.J., GLAI Study Investigators A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005, 28:1547-1554.
13. Gupta R., Gupta L.K. Improvement in long term and visuo-spatial memory following chronic pioglitazone in mouse model of Alzheimer's disease. Pharmacol. Biochem. Behav. 2012, 102(2):184-190.
14. Hansen M.B., Nielsen S.E., Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J. Immunol. Methods 1989, 119:203-210.
15. Hu H, Zou C, Xi X, Shi Z, Wang G, Huang X., in press. Protective effects of pioglitazone on renal ischemia-reperfusion injury in mice. J. Surg. Res.
16. Hwang J., Kleinhenz D.J., Lassegue B., Griendling K.K., Dikalov S., Hart C.M. Peroxisome proliferator-activated receptor-gamma ligands regulate endothelial membrane superoxide production. Am. J. Physiol. Cell Physiol. 2005, 288:C899-C905.
17. Ialenti A., Grassia G., Di Meglio P., Maffia P., Di Rosa M., Ianaro A. Mechanism of the anti-inflammatory effect of thiazolidinediones: relationship with the glucocorticoid pathway. Mol. Pharmacol. 2005, 67(5):1620-1628.
18. Inoue K., Kawahito Y., Tsubouchi Y., Kohno M., Yoshimura R., Yoshikawa T., Sano H. Expression of peroxisome proliferator activated receptor gamma in renal cell carcinoma and growth inhibition by its agonists. Biochem. Biophys. Res. Commun. 2001, 287:727-732.
19. Kim M.G., Yang H.N., Kim H.W., Jo S.K., Cho W.Y., Kim H.K. IL-10 mediates rosiglitazone-induced kidney protection in cisplatin nephrotoxicity. J. Korean Med. Sci. 2010, 25(4):557-563.
20. Kong X., Zhang D.Y., Wu H.B., Li F.X. Losartan and pioglitazone ameliorate nephropathy in experimental metabolic syndrome rats. Biol. Pharm. Bull. 2011, 34(5):693-699.
21. Lee S., Kim W., Moon S.O., Sung M.J., Kim D.H., Kang K.P., Jang Y.B., Lee J.E., Jang K.Y., Park S.K. Rosiglitazone ameliorates cisplatin-induced renal injury in mice. Nephrol. Dial. Transplant 2006, 21(8):2096-2105.
22. Lubet R.A., Fischer S.M., Steele V.E., Juliana M.M., Desmond R., Grubbs C.J. Rosiglitazone, a PPAR gamma agonist: potent promoter of hydroxybutyl (butyl) nitrosamine-induced urinary bladder cancers. Int. J. Cancer 2008, 123:2254-2259.
23. Ma L.J., Marcantoni C., Linton M.F., Fazio S., Fogo A.B. Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. Kidney Int. 2001, 59:1899-1910.
24. Moharam M.E., GamalEL-Deen A.M., ELSayed S.T. Production, immobilization and anti-tumor activity of l-asparaginase of Bacillus sp. R36. J. Am. Sci. 2010, 6(3):1-10.
25. Na H.K., Surh Y.J. Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands as bifunctional regulators of cell proliferation. Biochem. Pharmacol. 2003, 66(8):1381-1391.
26. Ohga S., Shikata K., Yozai K., Okada S., Ogawa D., Usui H., Wada J., Shikata Y., Makino H. Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation. Am. J. Physiol. Renal Physiol. 2007, 292(4):F1141-F1150.
27. Ozkaya O., Yavuz O., Can B., Dilek M., Savli E., Acikgoz Y., Bedir A., Akpolat T. Effect of rosiglitazone on cisplatin-induced nephrotoxicity. Ren. Fail. 2010, 32(3):368-371.
28. Pasceri V., Wu H.D., Willerson J.T., Yeh E.T. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 2000, 101(3):235-238.
29. Ramesh G., Reeves W.B. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J. Clin. Invest. 2002, 110(6):835-842.
30. Ramkalawan H., Wang Y.Z., Hurbungs A., Yang Y.F., Tian F.F., Zhou W.B., Li J., Yang H., Xiao B., Zhang W. Pioglitazone, PPAR-γ agonist attenuates experimental autoimmune neuritis. Inflammation 2012, 35(4):1338-1347.
31. Raphael K.L., Strait K.A., Stricklett P.K., Baird B.C., Piontek K., Germino G.G., Kohan D.E. Effect of pioglitazone on survival and renal function in a mouse model of polycystic kidney disease. Am. J. Nephrol. 2009, 30:468-473.
32. Reddy R.C., Srirangam A., Reddy K., Chen J., Gangireddy S., Kalemkerian G.P., Standiford T.J., Keshamouni V.G. Chemotherapeutic drugs induce PPAR-γ expression and show sequence-specific synergy with PPAR-γ ligands in inhibition of non-small cell lung cancer. Neoplasia 2008, 10:597-603.
33. Saleh S., Ain-Shoka A.A., El-Demerdash E., Khalef M.M. Protective effects of the angiotensin II receptor blocker losartan on cisplatin-induced kidney injury. Chemotherapy 2009, 55(6):399-406.
34. Sastry J., Kellie S.J. Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine. Pediatr. Hematol. Oncol. 2005, 22:441-445.
35. Satoh K. Serum lipid peroxide in cerebrovascular disorders determined by a new colorimetric method. Clin. Chim. Acta 1978, 90(1):37-43.
36. Shephard M.D., Mezzachi R.D. Scientific and Technical Committee, Technical Report No. 8. The collection, preservation, storage and stability of urine specimens for routine clinical biochemical analysis. Clin. Biochem. Rev. 1983, 4:61-67.
37. Somi M.H., Hajipour B., Asl N.A., Estakhri R., Azar A.N., Zade M.N., Haghjou A.G., Vatankhah A.M. Pioglitazone attenuates ischemia/reperfusion-induced liver injury in rats. Transplant. Proc. 2009, 41(10):4105-4109.
38. Sorg D.A., Buckner B. A simple method of obtaining venous blood from small laboratory animals. Proc. Soc. Exp. Biol. Med. 1964, 115:1131-1132.
39. Sugiyama Y., Taketomi S., Shimura Y., Ikeda H., Fujita T. Effects of pioglitazone on glucose and lipid metabolism in Wistar fatty rats. Arzneimittelforschung 1990, 40:263-267.
40. Tanaka Y., Hasegawa T., Chen Z., Okita Y., Okada K. Nephroprotective immunosuppression by pioglitazone with low-dose cyclosporine in rat heart transplantation. J. Thorac. Cardiovasc. Surg. 2009, 138(3):744-751.
41. Tawfik M.K. Renoprotective activity of telmisartan versus pioglitazone on ischemia/reperfusion induced renal damage in diabetic rats. Eur. Rev. Med. Pharmacol. Sci. 2012, 16(5):600-609.
42. Thal S.C., Heinemann M., Luh C., Pieter D., Werner C., Engelhard K. Pioglitazone reduces secondary brain damage after experimental brain trauma by PPAR-γ-independent mechanisms. J. Neurotrauma 2011, 28(6):983-993.
43. Tikoo K., Kumar P., Gupta J. Rosiglitazone synergizes anticancer activity of cisplatin and reduces its nephrotoxicity in 7, 12-dimethyl benz a anthracene (DMBA) induced breast cancer rats. BMC Cancer 2009, 9:107.
44. Vijay S.K., Mishra M., Kumar H., Tripathi K. Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in type-2 diabetes. Acta Diabetol. 2009, 46(1):27-33.
45. Yang F.G., Zhang Z.W., Xin D.Q., Shi C.J., Wu J.P., Guo Y.L., Guan Y.F. Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines. Acta Pharmacol. Sin. 2005, 26(6):753-761.
46. Yang H., Deleuze S., Zuo Y., Potthoff Sebastian.A., Ma L., Fogo A.B. The PPAR-γ agonist pioglitazone ameliorates aging-related progressive renal injury. J. Am. Soc. Nephrol. 2009, 20:2380-2388.
47. Yoshihara D., Kurahashi H., Morita M., Kugita M., Hiki Y., Aukema H.M., Yamaguchi T., Calvet J.P., Wallace D.P., Nagao S. PPAR-γamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease. Am. J. Physiol. Renal Physiol. 2011, 300(2):F465-F474.